MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
LNTH stock logo

LNTH

Lantheus Holdings, Inc.

$100.55
-0.25
 (-0.25%)
Exchange:  NASDAQ
Market Cap:  6.546B
Shares Outstanding:  18.032M
Delayed data
Calculate LNTH Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Mary Anne Heino
Full Time Employees:  1193
Address: 
201 Burlington Road
Bedford
MA
1730
US
Website:  https://www.lantheus.com
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company’s robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
LNLNTH logoLNTHLantheus Holdings, Inc.6.5B23.818.211.0%
AMAMRX logoAMRXAmneal Pharmaceuticals, Inc.6.0B34.220.113.4%
ALALKS logoALKSAlkermes plc7.3B114—2.1%
ININDV logoINDVIndivior Pharmaceuticals Inc4.4B12.18.3125.1%
RDRDY logoRDYDr. Reddy's Laboratories Limited10.2B29.319.55.8%
RGRGC logoRGCRegencell Bioscience Holdings Limited2.9B——-444.2%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,296,4291,533,9101,541,609
Gross Profit709,543988,291941,952
EBITDA491,005515,270403,639
Operating Income364,642456,979310,832
Net Income326,661312,442233,559

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets1,651,1491,980,3402,227,399
Total Liabilities835,257892,3291,137,602
Total Stockholders Equity815,8921,088,0111,089,797
Total Debt616,946619,438738
Cash and Cash Equivalents713,656912,814359,121

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow305,260544,750390,141
Capital Expenditure-46,555-51,625-36,089
Free Cash Flow258,705493,125354,052
Net Income326,661312,442233,559
Net Change in Cash298,044199,201-553,660

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)2,326,750.430Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,646,247.614Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)2,440,100Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)834,374.878Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)970,806.609Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)882,777.754Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)634,737.653Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)749,724.632Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)675,532.419Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)701,482.155Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)797,806.011Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)735,655.438Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)9.870Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)10.950Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)9.270Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.534B  ?P/S
 (TTM)
: 
4.19
?Net Income
 (TTM)
: 
312.442M  ?P/E
 (TTM)
: 
23.81
?Enterprise Value
 (TTM)
: 
6.559B  ?EV/FCF
 (TTM)
: 
12.87
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
23.27%  ?ROIC
 (TTM)
: 
11.03%
?Net Debt
 (TTM)
: 
-291509000  ?Debt/Equity
 (TTM)
: 
0.48
?P/B
 (TTM)
: 
4.98  ?Current Ratio
 (TTM)
: 
3.06

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
18.22Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates LNTH intrinsic value between $101.27 – $143.78 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about LNTH valuation

Is Lantheus Holdings, Inc. (LNTH) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Lantheus Holdings, Inc. (LNTH) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is LNTH a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LNTH trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is LNTH’s P/E ratio?

You can see LNTH’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for LNTH?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is LNTH a good long-term investment?

Whether LNTH fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

LNTH

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.25
MARKETSnap

Trading Metrics:

Open: 100.77   Previous Close: 100.8
Day Low: 100.48   Day High: 100.95
Year Low: 49.67   Year High: 111.86
Price Avg 50: 101.95   Price Avg 200: 85.99
Volume: 1.028M   Average Volume: 1.256M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?
11-09-2026 12:28
Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
10-09-2026 16:18
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
03-08-2026 09:36
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
RadioMedix Appoints Brian A. Markison to Board of Directors
15-07-2026 13:13
RadioMedix Appoints Brian A. Markison to Board of Directors
FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit
29-06-2026 09:51
FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit
US FDA declines to approve Lantheus' tumor imaging kit
26-06-2026 16:12
US FDA declines to approve Lantheus' tumor imaging kit

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read